Company intelligence / Profile preview
Centre for Chinese Herbal Medicine Drug Development
- Ownership
- Private
- Development stage
- Preclinical
Overview
CDD has advanced several proprietary herbal formulations into clinical development. Notably, CDD-2103 has shown promising preclinical results in ulcerative colitis models by promoting immune tolerance through regulatory T cell induction. The center’s lead programs are targeting gastrointestinal diseases with a focus on international pharmaceutical standards.
- Therapeutic areas
- GastroenterologyRare Diseases
- Modalities
- Herbal medicineSmall molecule (notably berberine and palmatine as identified active compounds in their pipeline)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Centre for Chinese Herbal Medicine Drug Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Centre for Chinese Herbal Medicine Drug Development.